Development of a Neurovirulent Testing System for Oral Poliovirus Vaccine with Transgenic Mice

Laboratory Animal Science

Volumn 47, Issue 2, 1997, Pages 118-120

  Levenbook, Inessa ^a,c   Nomura, Tatsuji ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

NONHUMAN; POLIOMYELITIS; REVIEW; TRANSGENIC MOUSE; VACCINE PRODUCTION; VIRUS VIRULENCE;

ANIMALS; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NERVOUS SYSTEM; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; RECEPTORS, VIRUS; SPINAL CORD;

EID: 0030916111     PISSN: 00236764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. World Health Organization. 1990. Requirements for poliomyelitis vaccine (oral). WHO Tech. Rep. Ser. 800:46-49.
2. Ren, R., F. Constantini, E. J. Gorgasz, et al. 1990. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63:353-362.
3. Koike, S., C. Taya, T. Kurata, et al. 1991. Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. USA 88:951-955.
4. Ren, R., E. G. Moss, and V. P. Racaniello. 1991. Identification of two determinants that attenuate vaccinerelated type 2 poliovirus. J. Virol. 65:1377-1382.
5. Ren, R., and V. Racaniello. 1992. Human poliovirus receptor gene expression and poliovirus tropism in transgenic mice. J. Virol. 66:296-304.
6. Racaniello, V., R. Ren, and M. Bouchard. 1993. Poliovirus attenuation and pathogenesis in transgenic mouse model for poliomyelitis. Develop. Biol. Stand. 78:109-116.
7. Koike, S., H. Horie, Y. Sato, et al. 1993. Poliovirus-sensitive transgenic mice as a new mechanism and practical aspects. Develop. Biol. Stand. 78:101-107.
8. Horie, H., S. Koike, T. Kurata, et al. 1994. Transgenic mice carrying the human poliovirus receptor: new animal model for study of poliovirus neurovirulence. J. Virol. 68:681-688.
9. Koike, S., C. Taya, J. Aoki, et al. 1994. Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene: influence of transgene expression on pathogenesis. Arch. Virol. 139:351-363.
10. World Health Organization. 1992. New approaches to poliovirus diagnosis using laboratory technique: memorandum from a WHO meeting. Bull. W.H.O. 70:27-33.
11. Dragunsky, E., D. Gardner, R. Taffs, et al. 1993. Transgenic PVR Tg-1 mice for testing of poliovirus type-3 neurovirulence: comparison with monkey test. Biologicals 21:233-237.
12. World Health Organization. 1990. Criteria for acceptance of vaccines after neurovirulence testing. In Requirements for poliomyelitis vaccine (oral). WHO Tech. Rep. Ser. 800:Appendix 3, annex 1.
13. World Health Organization. 1993. Meeting on transgenic mice susceptible to poliovirus as a model for neurovirulence tests of live poliomyelitis vaccine. Document WHO/MIM/ PVD/94.1. World Health Organization, Geneva.
14. Hioki, K., H. Kato, S. Endo, et al. 1993. Planned production of poliovirus-sensitive transgenic mice. Exp. Anim. 42:300-303 (in Japanese).
15. World Health Organization. 1993. Maintenance and distribution of transgenic mice susceptible to human viruses: memorandum from a WHO meeting. Bull. W.H.O. 71:497-502.
16. Abe, S., Y. Ota, S. Koike, et al. 1995. Neurovirulence test for oral poliovirus vaccines using poliovirus-sensitive transgenic mice. Virology 206:1075-1083.
17. Abe, S., Y. Ota, Y. Doi, et al. 1995. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for different temperature-sensitive viruses derived from the Sabin type 3 virus. Virology 210:160-166.
18. Dragunsky, E., R. Taffs, Y. Chernokhvostova, et al. 1996 A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine. Biologicals 24:77-86.
19. Chumakov, K. M., L. P. Powers, K. E. Noonan, et al. 1991. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA 88:199-203.
20. Rezapkin, G. V., K. M. Chumakov, Z. Lu, et al. 1994 Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202:370-378.
21. Taffs, R., K. Chumakov, G. Rezapkin, et al. 1995. Mutant selection in Sabin 2 strain grown in different cell culture conditions and genetic stability of oral poliovirus vaccine. Virology 209:366-373.
22. Wood, D. J. 1996. New approaches to poliovirus vaccine neurovirulence test: transgenic mice susceptible to poliovirus and molecular analysis of poliovirus: meeting report of the WHO global programme for vaccines and immunization and the WHO biological unit. Vaccine (in press).
23. Tatem, J. M., C. Weeks-Levy, A. Georgiu, et al. 1992 A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J. Virol. 66:3194-3197.
24. Chumakov, K. M., L. P. Norwood, M. L. Parker, et al. 1992. RNA sequence variants I in live poliovirus vaccine and their relation to neurovirulence. J. Virol. 66:966-970.
25. Contreras, G., J. Furesz, K. Karpinski, et al. 1988. Experience in Canada with the new revised monkey neurovirulence test for oral poliovirus vaccine. J. Biol. Stand. 16:195-205.
26. World Health Organization. 1995. Live oral poliovirus vaccine. In Manual of laboratory methods for potency testing of vaccines used in the WHO expanded programme on immunization. Document WHO/BLG/95.1, chap. 9, p. 67-74. World Health Organization, Geneva.
27. Marsden, S. A., L. R. Boulger, D. I. Magrath, et al. 1980 Monkey neurovirulence of live attenuated (Sabin) type I and type II poliovirus vaccines. J. Biol. Stand. 8:303-309.
28. Levenbook, I. Unpublished data.